GlobeNewswire Inc.··Researchandmarkets.ComSAPHNELO Poised for Strong Growth Despite FDA Setback on Subcutaneous Form
AstraZeneca's SAPHNELO generated $483M in nine months of 2025 with approval in 70+ countries, though FDA rejected subcutaneous formulation in February 2026.
AZNmonoclonal antibodyFDA approval